US FDA does not need to issue Written Confirmations by 2 July 2013
In a Press Release the US FDA announced that the U.S. is now a "listed country" with the European Commission (EC) so that U.S. companies need not obtain an export certificate from the FDA before shipping certain pharmaceutical products to Europe.
Without the waiver, all U.S. companies shipping active pharmaceutical ingredients (APIs) to Europe after July 1, 2013 would have had to first submit documentation from the FDA that the product was manufactured in accordance with Europe's good manufacturing practices. The EC has now approved that request following a comprehensive audit of the FDA's regulatory and inspectional oversight of APIs. The audit took place from May 13 - 20, 2013.
The European Commssion published the implementing decision on the Webpage.
Related GMP News
22.10.2025Content Review of the Audit Trail Review
15.10.2025Executing the Audit Trail Review
08.10.2025Risk-based Determination of the Scope and Frequency of Audit Trail Reviews
01.10.2025Decentralised Manufacturing: New UK Framework in Operation
24.09.2025Responsibilities for the Audit Trail (Review)
17.09.2025When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025